Back to Browse Journals » Journal of Receptor, Ligand and Channel Research » Volume 4

Specific mechanism of action of amisulpride in the treatment of schizophrenia and correlation with clinical response and tolerability

Authors Juruena MF, de Sena EP, de Oliveira IR

Published Date August 2011 Volume 2011:4 Pages 49—55

DOI http://dx.doi.org/10.2147/JRLCR.S6239

Published 26 August 2011

Mario F Juruena1, Eduardo Pondé de Sena2, Irismar Reis de Oliveira3
1Stress and Affective Disorders Programme, Department of Neuroscience and Behaviour, Faculty of Medicine of Ribeirao Preto, University of Sao Paulo, Sao Paulo, Brazil; 2Department of Pharmacology, Institute of Health Sciences, Federal University of Bahia, Salvador, Brazil; 3Department of Neurosciences and Mental Health, School of Medicine, Federal University of Bahia, Salvador, BA, Brazil

Abstract: The treatment of schizophrenia has advanced because the therapeutic efficacy, tolerability, and safety profiles of atypical antipsychotics seem to be superior to those of classical neuroleptics. Amisulpride is an atypical antipsychotic drug with a unique receptor pharmacology, which is dose-dependent. As could be predicted from the pharmacologic profile of a pure D2/D3 receptor blocker, amisulpride is an atypical antipsychotic agent, effective for positive and negative symptoms, which can bring about additional improvement in the social functioning and quality of life of patients with schizophrenia. Amisulpride has one of the lowest potentials for weight gain of all the antipsychotic agents, and is clearly associated with lower use of anti-parkinsonian medication and with fewer dropouts due to adverse events than conventional antipsychotics. Amisulpride is well tolerated in terms of anxiety and insomnia. Amisulpride has a pronounced prolactin-elevating effect which appears to be independent of dosage and duration of administration. Hyperprolactinemia rapidly reverses after amisulpride discontinuation. Amisulpride benefits patients with negative symptoms, and is the only antipsychotic to demonstrate efficacy in patients with predominantly negative symptoms. Amisulpride maintains its efficacy when used for medium-/long-term treatment, as demonstrated in studies of up to 12 months. Amisulpride has the best evidence as an effective adjunct to clozapine treatment. In conclusion, amisulpride is an antipsychotic agent with proven efficacy and good tolerability.

Keywords: antipsychotic agents, amisulpride, adverse events, pharmacology

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Safety and tolerability of antipsychotics: focus on amisulpride

Mario F Juruena, Eduardo Pondé de Sena, Irismar Reis de Oliveira

Drug, Healthcare and Patient Safety 2010, 2:205-211

Published Date: 1 October 2010

Readers of this article also read:

A tissue-engineered subcutaneous pancreatic cancer model for antitumor drug evaluation

He Q, Wang X, Zhang X, Han H, Han B, Xu J, Tang K, Fu Z, Yin H

International Journal of Nanomedicine 2013, 8:1167-1176

Published Date: 19 March 2013

Cancer stem cell theory: therapeutic implications for nanomedicine

Wang K, Wu X, Wang J, Huang J

International Journal of Nanomedicine 2013, 8:899-908

Published Date: 28 February 2013

An update on mindfulness meditation as a self-help treatment for anxiety and depression

Edenfield TM, Saeed SA

Psychology Research and Behavior Management 2012, 5:131-141

Published Date: 23 October 2012

Radio electric asymmetric brain stimulation in the treatment of behavioral and psychiatric symptoms in Alzheimer disease

Mannu P, Rinaldi S, Fontani V, Castagna A

Clinical Interventions in Aging 2011, 6:207-211

Published Date: 26 July 2011

Safety and tolerability of antipsychotics: focus on amisulpride

Mario F Juruena, Eduardo Pondé de Sena, Irismar Reis de Oliveira

Drug, Healthcare and Patient Safety 2010, 2:205-211

Published Date: 1 October 2010

Baseline characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment nonadherence

Katarina Kelin, Alan JM Brnabic, Richard Newton, et al

Patient Preference and Adherence 2010, 4:301-311

Published Date: 11 August 2010

Etiology, prevalence, and treatment of dry eye disease

Johnny L Gayton

Clinical Ophthalmology 2009, 3:405-412

Published Date: 7 July 2009

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009

Local anesthetic failure associated with inflammation: verification of the acidosis mechanism and the hypothetic participation of inflammatory peroxynitrite

Takahiro Ueno, Hironori Tsuchiya, Maki Mizogami, Ko Takakura

Journal of Inflammation Research 2008, 1:41-48

Published Date: 13 November 2008